3/26
01:06 pm
bmea
Biomea Fusion, Inc. (NASDAQ: BMEA) was given a new $10.00 price target on by analysts at Oppenheimer Holdings Inc..
Low
Report
Biomea Fusion, Inc. (NASDAQ: BMEA) was given a new $10.00 price target on by analysts at Oppenheimer Holdings Inc..
3/25
07:00 pm
bmea
Biomea Fusion Announces Leadership Transition
Medium
Report
Biomea Fusion Announces Leadership Transition
3/24
02:53 pm
bmea
Biomea Fusion, Inc. (NASDAQ: BMEA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Low
Report
Biomea Fusion, Inc. (NASDAQ: BMEA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
3/24
08:37 am
bmea
Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose [Yahoo! Finance]
Low
Report
Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose [Yahoo! Finance]
3/24
08:30 am
bmea
Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose
Medium
Report
Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose
3/19
08:04 am
bmea
Biomea Fusion, Inc. (NASDAQ: BMEA) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $16.00 price target on the stock.
Medium
Report
Biomea Fusion, Inc. (NASDAQ: BMEA) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $16.00 price target on the stock.
3/3
08:00 am
bmea
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
High
Report
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
2/27
08:00 am
bmea
Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes
Medium
Report
Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes
1/14
08:02 am
bmea
Biomea Fusion, Inc. (NASDAQ: BMEA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Low
Report
Biomea Fusion, Inc. (NASDAQ: BMEA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
1/13
09:00 am
bmea
Biomea Fusion to Become a Diabetes & Obesity Medicines Company
High
Report
Biomea Fusion to Become a Diabetes & Obesity Medicines Company
1/10
08:03 am
bmea
Biomea Fusion, Inc. (NASDAQ: BMEA) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $128.00 price target on the stock.
Medium
Report
Biomea Fusion, Inc. (NASDAQ: BMEA) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $128.00 price target on the stock.
1/7
09:00 am
bmea
Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study
Low
Report
Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study
1/6
07:00 am
bmea
Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Medium
Report
Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference